Limantrafin
Limantrafin (CB-103) is a first-in-class, orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex. Limantrafin has anti-tumor activity[1][2][3][4].
Product Specifications
CAS Number
218457-67-1
Product Name Alternative
CB-103
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Notch
Type
Reference compound
Related Pathways
Neuronal Signaling; Stem Cell/Wnt
Applications
Neuroscience-Neuromodulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/limantrafin.html
Purity
99.97
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC1=CC=C(OC2=CC=C(C(C)(C)C)C=C2)N=C1
Molecular Formula
C15H18N2O
Molecular Weight
242.32
Precautions
H302, H315, H319, H335
References & Citations
[1]Freddy Radtke, et al. Inhibitors of notch signalling pathway and use thereof in treatment of cancers. US9296682B2.|[2]R.Lehal, et al. Development of a novel first-in-class oral inhibitor of the NOTCH pathway.|[3]Rajwinder Lehal, et al. Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway.|[4]Jose Manuel Perez Garcia, et al. First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
